: WSJ: Carl Icahn says Grail deal cost Illumina shareholders $50 billion


Shares of Illumina Inc. ILMN, -4.24% were up about 8% in premarket trading on Monday after the Wall Street Journal reported Sunday that Carl Icahn is planning a proxy fight. The billionaire activist reportedly believes that the company’s $7.1 billion acquisition of cancer-test maker Grail cost shareholders $50 billion. Regulators in the U.S. and Europe have attempted to block the deal. Icahn plans to nominate three people to the Illumina board on Monday, the Journal reported. Illumina’s stock has declined 36.1% over the past year, while the broader S&P 500 SPX, -1.45% is down 7.8%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: First Republic Bank’s stock slides amid continuing jitters about regional banks
Next articleBiden to speak at 9 a.m. about weekend actions to stabilize U.S. banking system


Please enter your comment!
Please enter your name here